Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cartilage Healing Approach Merging Polymer InnOvation with Nature

Project description

Novel treatment for focal cartilage defects in the knee

The treatment of cartilage injury has evolved in recent years with the development of reparative and restorative methods. Procedures are aimed at both alleviating the symptoms and limiting the progression of cartilage damage into degenerative disease. The EU-funded CHAMPION project is targeting focal knee cartilage defects, which are as painful and limiting as osteoarthritis and can require total knee replacement surgery. The project is preparing to market GelrinC, a simple, off-the-shelf treatment for focal injuries in the knee cartilage. GelrinC was designed to support the formation of hyaline cartilage by forming a cell barrier that prevents migration of undesired cells into the defect. CHAMPION is already regulatory-ready for commercialisation in Europe.

Objective

Cartilage injury afflicts over one million patients annually in Europe. Focal knee cartilage defects are as painful and limiting as osteoarthritis and can lead further degradation requiring total knee replacement surgery. Focal knee cartilage injuries are typically treated by bone marrow stimulation (Microfracture) which has limited benefit due to a high failure rate, poor longterm outcome and frequent required re-interventions. Alternative therapeutic products in the form of cellular/biologicals treatments have failed due to complexity and multiple surgery risks. With the promise of cell-based procedures not realized, the pursuit of an optimal treatment for symptomatic articular cartilage defects in the knee joint remains elusive. GelrinC is a simple, off-the-shelf treatment for focal injuries in the knee cartilage. It is a ready-to-use liquid cured in-situ by ultraviolet light to form a resorbable implant conforming to the shape and depth of the defect. Unlike other acellular implants, GelrinC was
designed to support the formation of hyaline cartilage through a unique Mode-of-Action: Formation of a cell barrier thus preventing migration of undesired cells into the defect. At the same time, GelrinC harnesses the established prochondrogenic potential of polyethylene glycol, its major component, to provide the right microenvironment for the body’s own stem cells to differentiate into chondrocytes. Due to the presence of the denatured human fibrinogen in GelrinC, the implant resorbs from the outside inwards and thus is gradually replaced with new hyaline-like cartilage in a synchronized process.
GelrinC gained a CE mark in 2017 and it is regulatory ready for commercialization in Europe. The next steps allowing quick, successful market entrance are optimizing the production process, completing a phase III clinical trials; and creating commercialization channels including centres of excellence in Europe.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

REGENTIS BIOMATERIALS LTD
Net EU contribution
€ 2 185 190,00
Address
HA ILAN STREET 2 NORTHERN INDUSTRIAL ZONE
30600 Or Akiva
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 121 700,00